Abstract
The risk of plague as a bioweapon has prompted increasing research efforts to develop plague vaccines due to its extreme virulence and the ease of its transmission. Subunit vaccines that contain F1 and LcrV antigens of Y. pestis have been tested for safety and immunogenicity, but doubts have been raised about whether subunit vaccines that engender antibody responses will protect against pneumonic plague, which requires both humeral and cellular immune responses for protection. The live, attenuated vaccine EV76, a pgm locus deficient Y. pestis strain, has been used for a long time in the Former Soviet Union and some Asian countries, but is not commercially available in the US and Europe due to safety concerns. However, the live attenuated Y. pestis vaccines are still considered to be the most effective way to prevent plague. In this review, we present our opinions about rationally creating live, safe and immunogenic Y. pestis vaccines with potential use for human based on established researches.
Keywords: Immune response, Live attenuated Y. pestis vaccines, Plague, Yersinia pestis.
Current Pharmaceutical Biotechnology
Title:Rational Considerations about Development of Live Attenuated Yersinia pestis Vaccines
Volume: 14 Issue: 10
Author(s): Wei Sun and Roy Curtiss
Affiliation:
Keywords: Immune response, Live attenuated Y. pestis vaccines, Plague, Yersinia pestis.
Abstract: The risk of plague as a bioweapon has prompted increasing research efforts to develop plague vaccines due to its extreme virulence and the ease of its transmission. Subunit vaccines that contain F1 and LcrV antigens of Y. pestis have been tested for safety and immunogenicity, but doubts have been raised about whether subunit vaccines that engender antibody responses will protect against pneumonic plague, which requires both humeral and cellular immune responses for protection. The live, attenuated vaccine EV76, a pgm locus deficient Y. pestis strain, has been used for a long time in the Former Soviet Union and some Asian countries, but is not commercially available in the US and Europe due to safety concerns. However, the live attenuated Y. pestis vaccines are still considered to be the most effective way to prevent plague. In this review, we present our opinions about rationally creating live, safe and immunogenic Y. pestis vaccines with potential use for human based on established researches.
Export Options
About this article
Cite this article as:
Sun Wei and Curtiss Roy, Rational Considerations about Development of Live Attenuated Yersinia pestis Vaccines, Current Pharmaceutical Biotechnology 2013; 14 (10) . https://dx.doi.org/10.2174/1389201014666131226122243
DOI https://dx.doi.org/10.2174/1389201014666131226122243 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Roles of Prostanoids in Colon Carcinogenesis and their Potential Targeting for Cancer Chemoprevention
Current Pharmaceutical Design The Escalating Challenge of Vancomycin Resistance in Staphylococcus aureus
Current Drug Targets - Infectious Disorders Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry Will Antirheumatic Treatment Improve Cardiovascular Outcomes in Patients with Rheumatoid Arthritis?
Current Pharmaceutical Design Mesenchymal Stem Cells and their Exosomes: Promising Therapeutics for Chronic Pain
Current Stem Cell Research & Therapy The Development of Stem Cell-Based Treatment for Liver Failure
Current Stem Cell Research & Therapy The Effects of Obesity on the Cerebral Vasculature
Current Vascular Pharmacology Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry Fractionation Techniques Improve the Proteomic Analysis of Human Serum
Current Pharmaceutical Analysis Peptides in Melanoma Therapy
Current Pharmaceutical Design Advances in Oncolytic Virus Therapy for Glioma
Recent Patents on CNS Drug Discovery (Discontinued) Methamphetamine and HIV Infection, Role in Neurocognitive Dysfunction
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways
Current Drug Targets Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Gene Microarray Analyses of Daboia russelli russelli Daboiatoxin Treatment of THP-1 Human Macrophages Infected with Burkholderia pseudomallei.
Current Molecular Medicine Abscisic Acid: A Phytohormone and Mammalian Cytokine as Novel Pharmacon with Potential for Future Development into Clinical Applications
Current Medicinal Chemistry Oxidative stress and Parkinson’s disease: New hopes in treatment with herbal antioxidants
Current Pharmaceutical Design Hydroxyimine NO-Donors; FK409 and Derivatives
Current Topics in Medicinal Chemistry